- Home
- LQDA vs ASGN Comparison
LQDA vs ASGN Comparison
Compare LQDA & ASGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- ASGN
- Stock Information
- Founded
- LQDA 2004
- ASGN 1985
- Country
- LQDA United States
- ASGN United States
- Employees
- LQDA N/A
- ASGN N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- ASGN Professional Services
- Sector
- LQDA Health Care
- ASGN Consumer Discretionary
- Exchange
- LQDA Nasdaq
- ASGN Nasdaq
- Market Cap
- LQDA 2.5B
- ASGN 2.1B
- IPO Year
- LQDA 2018
- ASGN 1992
- Fundamental
- Price
- LQDA $32.15
- ASGN $45.67
- Analyst Decision
- LQDA Strong Buy
- ASGN Hold
- Analyst Count
- LQDA 10
- ASGN 5
- Target Price
- LQDA $37.40
- ASGN $46.60
- AVG Volume (30 Days)
- LQDA 2.7M
- ASGN 632.6K
- Earning Date
- LQDA 11-03-2025
- ASGN 10-22-2025
- Dividend Yield
- LQDA N/A
- ASGN N/A
- EPS Growth
- LQDA N/A
- ASGN N/A
- EPS
- LQDA N/A
- ASGN 2.96
- Revenue
- LQDA $69,216,000.00
- ASGN $3,985,300,000.00
- Revenue This Year
- LQDA $424.31
- ASGN N/A
- Revenue Next Year
- LQDA $359.32
- ASGN $0.62
- P/E Ratio
- LQDA N/A
- ASGN $15.52
- Revenue Growth
- LQDA 343.41
- ASGN N/A
- 52 Week Low
- LQDA $10.37
- ASGN $39.25
- 52 Week High
- LQDA $32.41
- ASGN $95.29
- Technical
- Relative Strength Index (RSI)
- LQDA 70.67
- ASGN 54.92
- Support Level
- LQDA $27.76
- ASGN $39.25
- Resistance Level
- LQDA $30.50
- ASGN $46.03
- Average True Range (ATR)
- LQDA 1.85
- ASGN 1.71
- MACD
- LQDA 0.36
- ASGN 0.32
- Stochastic Oscillator
- LQDA 98.23
- ASGN 88.74
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.